Long-term course of opioid addiction

Harvard Review of Psychiatry

Volumn 23, Issue 2, 2015, Pages 76-89

  Hser, Yih Ing ^a   Evans, Elizabeth ^a   Grella, Christine ^a   Ling, Walter ^a   Anglin, Douglas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Criminality; Long term course; Medication assisted treatment; Opioid addiction; Substance use disorder

Indexed keywords

ALCOHOL; BUPRENORPHINE; METHADONE; NALTREXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ABSTINENCE; COMORBIDITY; CRIMINAL JUSTICE; DISEASE COURSE; EMPLOYMENT; FAMILY; HUMAN; METHADONE TREATMENT; MORBIDITY; MORTALITY; OPIATE ADDICTION; PHYSICAL ABUSE; PRIORITY JOURNAL; RELAPSE; REVIEW; SEXUAL ABUSE; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; COHORT ANALYSIS; OPIOID-RELATED DISORDERS;

ANALGESICS, OPIOID; BUPRENORPHINE; COHORT STUDIES; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 84925352953     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000052     Document Type: Review

References (111)

1. United Nations Office on Drug and Crime.World drug report 2013. Vienna: UNODC, 2013.
2. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994;2:244-68.
3. National Institute on Drug Abuse. Drug facts: heroin.Oct 2014. http://www.drugabuse.gov/publications/drugfacts/heroin
4. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: SAMHSA, 2013. http://www.samhsa.gov/data/sites/default/files/NSDUHnationalfindingresults2012/NSDUHnationalfindingresults2012/NSDUHresults2012.pdf
5. Hser YI, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001;58:503-8.
6. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1564-74.
7. Leshner AI. Addiction is a brain disease, and itmatters. Science 1997;278:45-7.
8. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95.
9. Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012;15:ES9-38.
10. Hser YI, Longshore D, Anglin MD. The life course perspective on drug use: a conceptual framework for understanding drug use trajectories. Eval Rev 2007;31:515-47.
11. Haastrup S, Jepsen PW. Seven year follow-up of 300 young drug abusers. Acta Psychiatr Scand 1984;70:503-9.
12. Judson BA, Goldstein A. Prediction of long-term outcome for heroin addicts admitted to amethadone maintenance program. Drug Alcohol Depend 1982;10:383-91.
13. Simpson DD, Sells SB. Opioid addiction and treatment: a 12-year follow-up. Malabar, FL; Krieger, 1990.
14. Mufti KA, Said S, Farooq S, et al. Five year follow up of 100 heroin addicts in Peshawar. J Ayub Med Coll Abbottabad 2004;16:5-9.
15. Judson BA, Ortiz S, Crouse L, Carney TM, Goldstein A. A follow-up study of heroin addicts five years after first admission to amethadone treatment program. Drug Alcohol Depend 1980;6:295-313.
16. Rathod NH, Addenbrooke WM, Rosenbach AF. Heroin dependence in an English town: 33-year follow-up. Br J Psychiatry 2005;187:421-5.
17. Chapple PA, Somekh DE, Taylor ME. Follow-up of cases of opiate addiction from the time of notification to the Home Office. Br Med J 1972;2:680-3.
18. Goldstein A, Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995;40:139-50.
19. Jimenez-Trevino L, Saiz PA, Garcia-Portilla MP, et al. A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav 2011; 36:1184-90.
20. Oppenheimer E, Stimson GV, Thorley A. Seven-year follow-up of heroin addicts: abstinence and continued use compared. Br Med J 1979;2:627-30.
21. Sheehan M, Oppenheimer E, Taylor C. Opiate users and the first years after treatment: outcome analysis of the proportion of follow up time spent in abstinence. Addiction 1993;88: 1679-89.
22. Whitty M, O'Connor J. Opiate dependence and pregnancy: 20-year follow-up study. Psychol Bull 2007;31:450-3.
23. Comiskey C, Kelly P, Leckey Y, et al. The ROSIE Study: drug treatment outcomes in Ireland. A report from the National Advisory Committee on Drugs. Dublin: Stationery Office, 2009.
24. Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction 2003;98:291-303.
25. Mehta SH, Sudarshi D, Srikrishnan AK, et al. Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction 2012;107:349-58.
26. Oppenheimer E, Stimson GV. Seven year follow-up of heroin addicts: life histories summarised. Drug Alcohol Depend 1982; 9:153-9.
27. Price RK, Risk NK, Spitznagel EL. Remission from drug abuse over a 25-year period: patterns of remission and treatment use. Am J Public Health 2001;91:1107-13.
28. Darke S, Ross J, Mills KL, Williamson A, Havard A, Teesson M. Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addict Behav 2007;32:1897-906.
29. Maddux JF, Desmond DP. Residence relocation inhibits opioid dependence. Arch Gen Psychiatry 1982;39:1313-7.
30. Skinner ML, Haggerty KP, Fleming CB, Catalano RF, Gainey RR. Opiate-addicted parents in methadone treatment: long-term recovery, health, and family relationships. J Addict Dis 2011;30:17-26.
31. Vaillant GE. A 20-year follow-up of New York narcotic addicts. Arch Gen Psychiatry 1973;29:237-41.
32. Genberg BL, Gange SJ, Go VF, et al. The effect of neighborhood deprivation and residential relocation on long-terminjection cessation among injection drug users (IDUs) in Baltimore, Maryland. Addiction 2011;106:1966-74.
33. Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort, 1988-2000: description and determinants. Am J Epidemiol 2003;158:695-704.
34. Grella CE, Lovinger K. 30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California. Drug Alcohol Depend 2011;118: 251-8.
35. Hser YI, Huang D, Chou CP, Anglin MD. Trajectories of heroin addiction: growth mixture modeling results based on a 33-year follow-up study. Eval Rev 2007;31:548-63.
36. Robins LN, Slobodyan S. Post-Vietnam heroin use and injection by returning US veterans: clues to preventing injection today. Addiction 2003;98:1053-60.
37. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965;193:646-50.
38. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and the future in mainstream medicine. Ann N Y Acad Sci 2000;909:186-216.
39. Termorshuizen F, Krol A, Prins M, van Ameijden EJ. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 2005;161:271-9.
40. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend 2009;105:83-8.
41. Stover H, Michels II. Drug use and opioid substitution treatment for prisoners. Harm Reduct J 2010;7:17.
42. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer, 1991.
43. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32-51.
44. Haastrup S, Jepsen PW. Eleven year follow-up of 300 young opioid addicts. Acta Psychiatr Scand 1988;77:22-6.
45. Robins LN, Davis DH, Goodwin DW. Drug use by U.S. Army enlistedmen in Vietnam: a follow-up on their return home. Am J Epidemiol 1974;99:235-49.
46. Hser YI. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis 2007;26:51-60.
47. Nosyk B, Anglin MD, Brecht ML, Lima VD, Hser YI. Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study. Am J Epidemiol 2013;177:675-82.
48. Hser YI, Anglin MD, Grella C, Longshore D, Prendergast ML. Drug treatment careers. A conceptual framework and existing research findings. J Subst Abuse Treat 1997;14:543-58.
49. Hoffman V, Smith LV, Grella CE, Hser YI, Anglin MD. A 33-year follow-up of narcotics addicts: aging, mortality, and disease. Paper presented at the annual meeting of the American Public Health Association, New York, NY, November 1996.
50. Hamilton AB, Grella CE. Gender differences among older heroin users. J Women Aging 2009;21:111-24.
51. Scherbaum N, Specka M. Factors influencing the course of opiate addiction. Int J Methods Psychiatr Res 2008;17 suppl 1: S39-44.
52. Eland-Goossensen MA, van de Goor IA, Benschop AJ, Garretsen HF. Profiles of heroin addicts in different treatment conditions and in the community. J Psychoactive Drugs 1998; 30:11-20.
53. Rounsaville BJ, Kleber HD. Untreated opiate addicts. How do they differ from those seeking treatment? Arch Gen Psychiatry 1985;42:1072-7.
54. Waldorf D. Natural recovery from opiate addiction: some social-psychological processes of untreated recovery. J Drug Issues 1983;13:237-80.
55. Klingemann KH, Efionayi-Mader D. [How much treatment does a person need? Addiction, spontaneous remission and "family" as biographical as leitmotiv]. Schweiz Rundsch Med Prax 1994;83:937-49.
56. Rosen CS, Ouimette PC, Sheikh JI, Gregg JA, Moos RH. Physical and sexual abuse history and addiction treatment outcomes. J Stud Alcohol 2002;63:683-7.
57. Branstetter SA, Bower EH, Kamien J, Amass L. A history of sexual, emotional, or physical abuse predicts adjustment during opioid maintenance treatment. J Subst Abuse Treat 2008; 34:208-14.
58. Frye V, El-Bassel N, Gilbert L, Rajah V, Christie N. Intimate partner sexual abuse among women on methadone. Violence Vict 2001;16:553-64.
59. Kang SY, Magura S, Laudet A, Whitney S. Adverse impact of child-abuse victimization among substance-using women in treatment. J Interpers Violence 1999;14:657-70.
60. Schäfer M, Schnack B, Soyka M. [Sexual and physical abuse during early childhood or adolescence and later drug addiction]. Psychother Psychosom Med Psychol 2000;50:38-50.
61. Westermeyer J, Wahmanholm K, Thuras P. Effects of childhood physical abuse on course and severity of substance abuse. Am J Addict 2001;10:101-10.
62. Oviedo-Joekes E, Marchand K, Guh D, et al. History of reported sexual or physical abuse among long-term heroin users and their response to substitution treatment. Addict Behav 2011;36:55-60.
63. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A. Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res 2009; 166:7-14.
64. Tobutt C, Oppenheimer E, Laranjeira R. Health of cohort of heroin addicts from London clinics: 22 year follow up. BMJ 1996;312:1458.
65. Hser YI, Gelberg L, Hoffman V, Grella CE, McCarthy W, Anglin MD. Health conditions among aging narcotics addicts: medical examination results. J Behav Med 2004;27:607-22.
66. Grella CE, Lovinger K. Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav 2012;37: 306-12.
67. Swendsen J, Conway KP, Degenhardt L, et al. Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction 2010;105:1117-28.
68. Martins SS, Keyes KM, Storr CL, Zhu H, Chilcoat HD. Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2009;103:16-24.
69. Macleod J, Hickman M, Jones HE, et al. Early life influences on the risk of injecting drug use: case control study based on the Edinburgh Addiction Cohort. Addiction 2013;108:743-50.
70. Darke S, Ross J, Teesson M. The Australian Treatment Outcome Study (ATOS): what have we learnt about treatment for heroin dependence? Drug Alcohol Rev 2007;26:49-54.
71. Vaillant GE. A 12-year follow-up of New York narcotic addicts. III. Some social and psychiatric characteristics. Arch Gen Psychiatry 1966;15:599-609.
72. Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence: intake data from the National Treatment Outcome Research Study. Br J Psychiatry 2000;176:285-9.
73. Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC Study. Addict Behav 2009;34:498-504.
74. Joe GW, Chastain EL, Marsh KL, Simpson DD. Relapse. In: Simpson DD, Sells SB, eds. Opioid addiction and treatment: a 12-year follow-up. Malabar, FL: Krieger, 1990:121-36.
75. Darke S, Williamson A, Ross J, Teesson M, Lynskey M. Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Depend 2004;74:77-83.
76. Darke S, Ross J, Williamson A, Mills KL, Havard A, Teesson M. Borderline personality disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of heroin dependence. Addiction 2007;102:1140-6.
77. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;341:c3172.
78. Ball JC, Snarr RW. A test of the maturation hypothesis with respect to opiate addiction. Bull Narc 1969;21:9-13.
79. Harrington P, Cox TJ. A twenty-year follow-up of narcotic addicts in Tucson, Arizona. Am J Drug Alcohol Abuse 1979;6:25-37.
80. Nurco DN, Cisin IH, Balter MB. Addict careers. III. Trends across time. Int J Addict 1981;16:1357-72.
81. Savage LJ, Simpson DD. Drug use and crime during a four-year posttreatment follow-up. Am J Drug Alcohol Abuse 1981;8:1-16.
82. Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. Am J Drug Alcohol Abuse 1990;16:223-38.
83. Teesson M, Mills K, Ross J, Darke S, Williamson A, Havard A. The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS). Addiction 2008;103:80-8.
84. Hser YI, Anglin D, Powers K. A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry 1993;50:577-84.
85. Simpson DD, Joe GW, Bracy SA. Six-year follow-up of opioid addicts after admission to treatment. Arch Gen Psychiatry 1982;39:1318-23.
86. Rathod NH. Follow-up study of injectors in a provincial town. Drug Alcohol Depend 1977;2:1-21.
87. Schnittker J, John A. Enduring stigma: the long-term effects of incarceration on health. J Health Soc Behav 2007;48:115-30.
88. Wang EA, Green J. Incarceration as a key variable in racial disparities of asthma prevalence. BMC Public Health 2010;10:290.
89. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison - a high risk of death for former inmates. N Engl J Med 2007;356:157-65.
90. Farrell M, Marsden J. Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 2008;103:251-5.
91. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
92. Wood E,Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008;300:550-4.
93. Wood E, Montaner JS, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis 2003;188:1164-70.
94. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers - United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011 4;60: 1487-92.
95. Giraudon I, Vicente J, Matias J, Mounteney J, Griffiths P. Reducing drug related mortality in Europe - a seemingly intractable public health issue. Adicciones 2012;24:3-7.
96. Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore,Maryland, 1995-2009. Am J Public Health 2013;103:917-22.
97. Kelly JF, White WL, eds. Addiction recovery management: theory, research and practice. New York: Humana, 2010.
98. McLellan AT. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 2002;97:249-52.
99. Tai B, Saxon AJ, Ling W. Medication-assisted therapy for opioid addiction. J Food Drug Anal 2013;21:S13-5.
100. Coleman K, Austin BT, Brach C, Wagner EH. Evidence on the Chronic Care Model in the new millennium. Health Aff (Millwood) 2009;28:75-85.
101. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract 1998;1:2-4.
102. Federation of State Medical Boards. Model policy on DATA 2000 and treatment of opioid addiction in the medical office. Apr 2013. http://library.fsmb.org/pdf/2013-model-policy-treatment-opioid-addiction.pdf
103. Maxwell JC. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev 2011;30: 264-70.
104. Fischer B, Patra J, Cruz MF, Gittins J, Rehm J. Comparing heroin users and prescription opioid users in a Canadianmulti-site population of illicit opioid users. Drug Alcohol Rev 2008;27: 625-32.
105. Wu LT, Woody GE, Yang C, Blazer DG. How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med 2011;5:28-35.
106. Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008;22:99-111.
107. National Institute on Drug Abuse. Topics in brief: medication-assisted treatment for opioid addiction. Bethesda, MD: NIDA, 2012.
108. Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients ' reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med 2010;4:204-10.
109. Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 2010;105:300-8.
110. Volkow ND, Normand J. The international HIV/AIDS pandemic has been closely inter-twinedwith drug abuse and addiction from the time it began. Preface. Drug Alcohol Depend 2013;132 suppl 1:S1.
111. Hser YI, Chang L, Wang GJ, et al. Capacity building and collaborative research on cross-national studies in the Asian region. J Food Drug Anal 2013;21:S117-22.